Breast Cancer

Cassidy Lockwood was nominated for the 2024 CURE Extraordinary Healer Award for her exceptional patient-first care, expert knowledge and compassionate support of patients with cancer.

CURE® spoke with a physical therapist specializing in oncology to find out more about this condition some patients with cancer are at risk for.

RNA from the COVID-19 infection in patients with certain metastatic cancers may be associated with tumor shrinkage, but more research is necessary.

As a four-time cancer survivor, I can tell you that survivorship means many things to each survivor.

From producer Quincy Jones’ death from pancreatic cancer to an inspiring moment between The Rock and a fan at a store, here’s what’s happening in the cancer space this week.

An expert explains how attitudes towards lymphedema risk have evolved over the years.

Having a collection of prayers before, during and after a mammogram has helped ease my mind tremendously after having breast cancer.

An expert told CURE that Trodelvy's side effects, such as neutropenia and fatigue, can often be managed through dose adjustments.

MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from treatment with targeted therapies.

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and endocrinopathies.

The phase 2 INVINCIBLE-4 clinical trial is currently underway in patients with localized triple-negative breast cancer.

During October, the FDA approved drugs to treat diseases including breast cancer, lung cancer, leukemia and gastric cancer.

After my breast cancer diagnosis, I decided to take a more active role in my treatment plan, opting for radiation therapy over chemotherapy due to concerns about side effects.

From World Series tickets given to a pediatric patient with cancer to the death of David Harris, known as Cochise in “The Warriors,” at the age of 75, here is this week’s cancer news.

Preoccupied with other worries during October, a month full of cancer anniversaries, I reflect on how Pinktober caught up with me.

The agency is alerting patients and providers to not use the implantable devices, made for soft tissue such as breast tissue.

My daughter faced the difficult decision of balancing the potential benefits and risks of cancer treatment, including the long-term heart complications associated with Herceptin.

Receiving radiation therapy for breast cancers harboring TP53 germline variants may cause secondary cancers, but risk estimates are unconfirmed.

From “The Office” star opening up in a new interview to Charley Steiner revealing his multiple myeloma journey, here is this week’s cancer news.

Trodelvy shows effectiveness in real-world breast cancer treatment, even after receiving Enhertu therapy.

Patients with TNBC and HR+/HER2- breast cancer demonstrated safe treatment with preoperative radiation therapy with Keytruda.

A colleague and a patient with cancer each submitted nominating essays about an oncology nurse who made an impact in their lives.

As someone who disliked pink for years, it has grown on me over time, especially after having breast cancer.

From “Boy Meets World” actress Danielle Fishel discussing her breast cancer surgery to a young TikTok star dying from a rare liver cancer, here’s what’s happening in the cancer space this week.

When I underwent surgery for breast cancer, reconstruction was highly recommended, but I decided to remain flat — a decision I think about sometimes.

For some patients with breast cancer, ctDNA may have the potential to predict disease relapse after they have undergone surgery and chemotherapy.

When natural disasters come, they affect everybody, including people dealing with cancer. I hope for speedy recoveries to patients affected by Hurricane Helene.

From Jenna Fischer announcing her breast cancer diagnosis to Martha Davis and the Motels canceling concerts after her radiation therapy, here’s what’s happening in the cancer space this week.

The Food and Drug Administration (FDA) has approved Itovebi (inavolisib) with Ibrance (palbociclib) and Faslodex (fulvestrant) for certain patients with advanced or metastatic breast cancer.

For a subset of patients with inoperable or metastatic HR-positive/HER2-negative breast cancer, treatment with datopotamab deruxtecan improved progression-free survival.